China’s Breakthrough Obesity Drug Mazdutide Achieves Record Weight Loss in Global Study
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been…
Category: Research Insights
What 30 Days of Journaling Taught Me About Food Habits
Hi, I’m Mila —a recovering stress-eater, snack procrastinator, and occasional breakfast skipper. For years, I cycled through phases of “eating…
What is Ozempic Teeth: The Hidden Side Effect of Popular Weight Loss Drugs
In the world of weight loss medications, Ozempic has gained a reputation as a game-changer. Originally developed to manage type…
Obesity Temporarily Disrupts Liver’s Starvation Response Without Permanent Damage, Study Finds
Tokyo, Japan – A groundbreaking study from the University of Tokyo reveals that obesity causes temporary, but not permanent, disruptions in the…
Top Obesity Drug Stocks to Watch: The Companies Leading the Weight-Loss Revolution
The global obesity drug market is experiencing significant growth, with projections exceeding $150 billion annually in the coming decade. This…
Weight-Loss Jabs Could Slash Cancer Risk by 50%: A “Transformational” Breakthrough
Key Findings at a Glance The Study: How Weight-Loss Drugs Stack Up Against Surgery A landmark Israeli study (presented at the European Congress…
Tirzepatide vs. Semaglutide for Obesity: Which Weight-Loss Drug Works Better?
New SURMOUNT-5 Trial Results (2025) Key Takeaways ✅ Tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy). Background: The…